Pharmaceuticals, Biotechnology & Life Sciences

Insider selling spikes at Natera (NTLA) – what it signals for shareholders. Learn how executive divestments, valuation gaps, and litigation risk could affect the share price.

United Therapeutics insider trades show disciplined 10 b‑5(1) management—steady growth, solid pipeline, and no market‑timing red flags.

Insider buying surges at Avita Medical (CDI) as executives purchase thousands of shares, signaling confidence amid a 27% YTD decline.

Insider selling at TEMPUS AI signals portfolio rebalancing, not distress—focus on the company’s AI‑driven precision‑medicine roadmap and upcoming milestones for potential upside.

Moderna CFO James Mock buys 2,475 shares—showing insider confidence in Moderna’s mRNA strategy, biotech trends, and future growth potential.

How Chemomab’s new board shake‑up and insider sales could drive a strategic pivot and a potential price rebound.

Oncolytics insider sale: Yi Qingqing liquidates her 235 ADSs amid growing executive trades and a fast‑track REOLYSIN pipeline—what this means for investor confidence.

Fortrea Holdings insider trades reveal COO Morais’s cautious net purchase, signaling management confidence and a strategic growth outlook for investors.

Vertex insider sales stay routine, with Chief Legal Officer Liu Joy selling 828 shares at $439.91—a 4 % drop in holdings but no impact on long‑term value.

Precision BioSciences insiders buy RSUs, signaling confidence amid a price dip and hinting at future upside from upcoming clinical milestones.